ARTICLE | Clinical News
Eligix reports Phase I/II results
March 16, 2000 8:00 AM UTC
Eligix (Medford, Mass.) said that selective depletion of CD8+ lymphocytes from donor lymphocyte infusions may achieve remission in patients relapsing after bone marrow transplantation, with a reductio...